Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

48.11 +1.75 (+3.78%)
Streaming Delayed Price Updated: 11:03 AM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
News headline image
Why Shares in Novo Nordisk Lost Weight Today ↗
Via The Motley Fool
News headline image
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows ↗
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years. 
Via Benzinga
News headline image
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Abbott, Dexcom Draw Retail Buzz As RFK Jr. Urges Americans To Embrace Health Wearables ↗
Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom. 
Via Stocktwits
News headline image
Hims & Hers CEO Says 'No Way In Hell We're Gonna Cave On' Selling Compounded Obesity Drugs After Novo Nordisk Breakup ↗
Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the stock. 
Via Stocktwits
Topics Law Enforcement Lawsuit
News headline image
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail? ↗
Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry. 
Via Benzinga
News headline image
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly ↗
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio. 
Via Benzinga
News headline image
Why Did Hims and Hers Stock Crash on Monday? ↗
Via The Motley Fool
News headline image
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know ↗
Via The Motley Fool
News headline image
Hims & Hers Stock Rebounds After-Hours After Novo Nordisk Split Triggers Record Plunge — Retail Traders Stay Loyal ↗
On Stocktwits, 24-hour message volume around HIMS soared 6,717% — the fifth highest among healthcare stocks. It was the top trending ticker on the platform late Monday. 
Via Stocktwits
News headline image
Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’ ↗
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically... 
Via Stocktwits
News headline image
Why Novo Nordisk Stock Is Sinking Today ↗
Via The Motley Fool
Topics Stocks Supply Chain
News headline image
Stocks Rise, Oil Tumbles Despite Iran's Strikes On US Bases: What's Driving Markets Monday? ↗
Wall Street resilient as Iran fires missiles at U.S. bases in Qatar and Iraq, defying expectations in energy market. U.S. equities and gold up, bonds down. 
Via Benzinga
Topics Bonds
News headline image
Hims & Hers Stock Plunges As Novo Nordisk Ends Partnership Over Allegations Of Selling Knockoff Versions Of Wegovy ↗
Novo said that Hims & Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions... 
Via Stocktwits
Topics Law Enforcement
News headline image
Hims & Hers Health Stock Is Tumbling Monday: What's Happening? ↗
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company. 
Via Benzinga
News headline image
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern ↗
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals. 
Via Benzinga
News headline image
IBD 50's Hims Plummets After Novo Yanks Deal Over 'Deceptive' And 'Illegitimate' Wegovy Knockoffs ↗
Hims stock plummeted Monday after Novo Nordisk ended their collaboration over concerns about Hims' compounded semaglutide. 
Via Investor's Business Daily
Dow Futures Edge Lower As Iran Moves To Block Strait Of Hormuz: Exxon, Chevron, Occidental, Tesla Among Stocks In Focus ↗
Via Stocktwits
Topics Stocks
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation ↗
NOVO-NORDISK (NYSE:NVO) offers strong growth, high profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth stocks. 
Via Chartmill
News headline image
Watch Out, Novo Nordisk & Eli Lilly: Chinese Biotech Steps Into the Ring To Take On Global Weight-Loss Leaders ↗
Sciwind Biosciences is expanding its global footprint with licensing deals and early talks for overseas development, as it eyes a double-digit market share in China's fast-growing obesity drug sector. 
Via Stocktwits
News headline image
Novo Nordisk Gains Ground In Obesity Race As Amycretin, Wegovy Show Significant Weight Loss ↗
The company is advancing amycretin to Phase 3 and pursuing regulatory approval for a higher Wegovy dose. 
Via Stocktwits
News headline image
5 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
McDonald’s Is Down, But Long-Term Investors Can Still Take a Bite
Analysts are downgrading McDonald's and the stock may have further to fall, but as a long-term opportunity, it may be getting to a point of offering real value 
Via MarketBeat
News headline image
How Do Investors Really Feel About Novo Nordisk? ↗
 
Via Benzinga
News headline image
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl ↗
This dark horse candidate has emerged to take significant share in the weight-loss drugs space. 
Via Investor's Business Daily
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - A Strong Candidate for Value Investors ↗
NOVO-NORDISK A/S (NYSE:NVO) is a strong value stock with high profitability, solid growth, and an attractive valuation, making it a candidate for long-term investors. 
Via Chartmill
News headline image
Why Scholar Rock Shares Are Soaring Today ↗
Via The Motley Fool
Topics Stocks
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.